Interrogating the promise of long-acting HIV pre-exposure prophylaxis.
HIV prevention
PrEP choice
differentiated service delivery
long-acting PrEP
oral PrEP
pre-exposure prophylaxis
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
10
10
2022
revised:
03
11
2022
accepted:
04
11
2022
pubmed:
27
11
2022
medline:
24
1
2023
entrez:
26
11
2022
Statut:
ppublish
Résumé
Oral HIV pre-exposure prophylaxis (PrEP) is a well-established product that provides a safe and highly effective way for individuals to protect themselves against HIV infection. However, hopes of a significant reduction in HIV incidence have been disappointing because of low uptake, adherence challenges to a daily pill regimen, and consistently high discontinuation rates within 6 months of initiation. Long-acting agents have been long awaited for their potential to facilitate adherence and to offer a choice between PrEP products. As the first long-acting agents enter the market, with more poised to follow, questions around how to integrate long-acting agents into oral PrEP platforms, and what the potential advantages and pitfalls of this integration will be, now need to be considered.
Identifiants
pubmed: 36435632
pii: S1471-4914(22)00293-3
doi: 10.1016/j.molmed.2022.11.003
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-98Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of interests L.G.B. receives honoraria for advisory roles at Gilead Science, ViiV Healthcare, and Merck Pty Ltd. C.P. declares no conflict of interest.